[Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].

Multiple myeloma (MM) is an incurable clonal plasma cell dysplasia, the second most hematological malignancy which mainly develops in elderly population. With the emerging novel agents and laboratory methods, the diagnosis and treatment of MM have been significantly improved. In this update version, the rare subtypes of MM were supplemented to the diagnosis part, and blood or urine M protein was not mandatory as diagnostic criteria for active myeloma. In the risk stratification part, more accurate standards were added. As novel agents including carfilzomib, pomalidomide and selinexor have been approved by CFDA, more alternative combination regimens were available for relapse and refractory patients. Overwhelmingly, autologous stem cell transplantation (ASCT) still plays an irreplaceable role in MM treatment. In the supportive treatment section, the administration of thromboprophylaxis and denosumab were added.